A Phase 2 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer's Disease, Traumatic Brain Injury and Depression, sponsored by Avid Radiopharmaceuticals. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 5th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 2, and was the 5th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 4 started in 2014.
This study's enrollment of 179 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 31st largest by enrollment of the 95 interventional ones that give a count, is one of 8 that started in 2014, is one of 23 in phase 2, and was the 52nd registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects should meet inclusion and exclusion criteria for the companion protocol in addition to the criteria below.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Flortaucipir F18 · Procedure: Brain PET scan
IV injection, 370 MBq (10 mCi), up to two doses
Also known as: [F-18]T807, 18F-AV-1451, LY3191748, Tauvid
positron emission tomography (PET) scan of the brain
Number of Participants With Adverse Events Related to Flortaucipir Administration
Frequency of treatment-emergent adverse events considered related to flortaucipir administration by the study investigator. Related events with a frequency \> 1.5% are reported. (note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in "Adverse Events" section below).
Time frame: within 48 hours of drug administration
Flortaucipir PET Scan SUVr
Standard Uptake Value Ratio (SUVr) using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline and follow-up scans
| Milestone | Cognitively Impaired | Cognitively Normal |
|---|---|---|
| Started | 69 | 110 |
| Completed | 59 | 110 |
| Not completed | 10 | 0 |
| Withdrew: Physician decision | 5 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 |
Frequency of treatment-emergent adverse events considered related to flortaucipir administration by the study investigator. Related events with a frequency \> 1.5% are reported. (note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in "Adverse Events" section below).
| Participants | Cognitively Impaired | Cognitively Normal |
|---|---|---|
| Headache | 0 | 3 |
| Dysgeusia | 0 | 3 |
Standard Uptake Value Ratio (SUVr) using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Cognitively Impaired | Cognitively Normal |
|---|---|---|
| Baseline SUVr | 1.3983 ± 0.3641 | 1.004 ± 0.04871 |
| Follow-up Scan SUVr | 1.4404 ± 0.37426 | — |
Collected over AEs were collected at scan visit and for 48 hours after flortaucipir administration.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cognitively Impaired | 0/69 (0%) | 0/69 (0%) | 6/69 (8.7%) |
| Cognitively Normal | 0/110 (0%) | 0/110 (0%) | 16/110 (14.5%) |
| Event | Cognitively Impaired | Cognitively Normal |
|---|---|---|
| headacheNervous system disorders | 0/69 | 5/110 |
| blood pressure increasedInvestigations | 2/69 | 2/110 |
| dysgeusiaNervous system disorders | 0/69 | 3/110 |
| dry mouthGastrointestinal disorders | 0/69 | 2/110 |
| injection site painGeneral disorders | 1/69 | 1/110 |
| palpitationsCardiac disorders | 1/69 | 0/110 |
| nasopharyngitisInfections and infestations | 1/69 | 0/110 |
| insomniaPsychiatric disorders | 1/69 | 0/110 |
| dizzinessNervous system disorders | 0/69 | 1/110 |
| paraesthesiaNervous system disorders | 0/69 | 1/110 |
| Age, Continuous(years) | Cognitively Impaired | Cognitively Normal | Total |
|---|---|---|---|
| Mean | 72.7 ± 7.6 | 70.4 ± 8.18 | 71.3 ± 8.02 |
| Sex: Female, Male(Participants) | Cognitively Impaired | Cognitively Normal | Total |
|---|---|---|---|
| Female | 34 | 68 | 102 |
| Male | 35 | 42 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Cognitively Impaired | Cognitively Normal | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 10 | 10 |
| Not Hispanic or Latino | 69 | 100 | 169 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cognitively Impaired | Cognitively Normal | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 5 | 5 | 10 |
| White | 62 | 105 | 167 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cognitively Impaired | Cognitively Normal | Total |
|---|---|---|---|
| United States | 69 | 110 | 179 |
| MMSE(score on a scale) | Cognitively Impaired | Cognitively Normal | Total |
|---|---|---|---|
| Mean | 21 ± 4.35 | 29.3 ± 1.06 | 26.1 ± 4.92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Jun 2019, 54 months.
Results were first posted in Sep 2020, 1 year 2 months after primary completion.
Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 54 months is above that.
Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir